Upcoming Anticipated Clinical Milestones AMPLIFY-201: Provide updated RFS and OS data in an oral presentation at the 2024 ESMO Immuno-Oncology Congress, taking place from December 11-13, 2024, in ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2024 taking place 11-13 December in Geneva, Switzerland. Abstracts will be made available on the ESMO I-O website ...

Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, ranked among the nation's top 5 cancer centers by U.S. News ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

NIAGARA received a warm reception when it was presented at the ESMO cancer congress, with discussant Petros Grivas from the University of Washington and Fred Hutchinson Cancer Center in Seattle ...

In July, Immutep reported updated positive efficacy and safety results from Cohort B of the TACTI-003 Phase IIb trial at an ESMO Virtual Plenary session ... chemotherapy in patients with CPS <1. The ...

"These data add to the body of evidence for Taiho Oncology's expanding hematology portfolio and demonstrate our continued commitment to bring innovative therapies to patients with cancer." ...

Welcome to Medscape's ESMO 2017 Live Blog. Throughout the ESMO 2017 Congress in Madrid, experts from across a range of cancer tumor types will provide real-time coverage of the most important ...